CPD

Across TCGA pan-cancer cohorts, CPD mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CPD data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CPD mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CPD expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CCRCC, LUAD, and UCEC are the cancer types where CPD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.387	0.720	.003	19	view →
LUAD	DFS	Quartile	All	0.377	0.761	.002	16	view →
UCEC	OS	Quartile	All	1.000	0.834	.028	12	view →
HNSC	OS	Median	II,III,IV	0.933	0.992	.024	4	view →
PDAC	DFS	Median	All	0.264	0.429	.039	4	view →
LSCC	OS	Tertile	All	0.812	0.950	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CPD–CCRCC (DFS)

Open the CCRCC breakdown →